Comparison of treatment results of 3 intensified regimens with CHOP-21
Regimen compared with CHOP-21 . | No complete remission . | . | . | Progressive disease . | . | . | EFS event . | . | . | Death . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OR . | 95% Cl . | P . | OR . | 95% Cl . | P . | RR . | 95% Cl . | P . | RR . | 95% Cl . | P . | ||||||||
| CHOP-14 | 1.10 | 0.66-1.86 | .710 | 0.54 | 0.24-1.21 | .136 | 0.93 | 0.66-1.29 | .652 | 0.61 | 0.38-0.99 | .048 | ||||||||
| CHOEP-21 | 0.72 | 0.42-1.25 | .248 | 0.67 | 0.32-1.42 | .294 | 0.69 | 0.49-0.97 | .035 | 0.74 | 0.47-1.15 | .183 | ||||||||
| CHOEP-14 | 0.43 | 0.23-0.80 | .007 | 0.30 | 0.12-0.79 | .014 | 0.65 | 0.46-0.92 | .017 | 0.60 | 0.37-0.96 | .034 | ||||||||
Regimen compared with CHOP-21 . | No complete remission . | . | . | Progressive disease . | . | . | EFS event . | . | . | Death . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OR . | 95% Cl . | P . | OR . | 95% Cl . | P . | RR . | 95% Cl . | P . | RR . | 95% Cl . | P . | ||||||||
| CHOP-14 | 1.10 | 0.66-1.86 | .710 | 0.54 | 0.24-1.21 | .136 | 0.93 | 0.66-1.29 | .652 | 0.61 | 0.38-0.99 | .048 | ||||||||
| CHOEP-21 | 0.72 | 0.42-1.25 | .248 | 0.67 | 0.32-1.42 | .294 | 0.69 | 0.49-0.97 | .035 | 0.74 | 0.47-1.15 | .183 | ||||||||
| CHOEP-14 | 0.43 | 0.23-0.80 | .007 | 0.30 | 0.12-0.79 | .014 | 0.65 | 0.46-0.92 | .017 | 0.60 | 0.37-0.96 | .034 | ||||||||
*Logistic regression adjusted for the strata stages III/IV and bulky disease (OR).
†No complete remission: partial response, stable disease, progressive disease, therapy-associated deaths, unknown response, additional therapy.
‡Cox proportional models adjusted for the strata stages III/IV and bulky disease (RR).
§EFS events: progression, no complete remission at the end of treatment, relapse after complete remission, death, unplanned additional treatment or change of treatment, whatever comes first.